TELO
TELOMIR PHARMA (TELO)
NASDAQ
$1.24$0.00 (0.00%)
Price as of Jun 03, 2026 7:23 PM EDT
  • $89.4M
    Market Cap
  • -39.22%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
12/31/2023
Income Statement
Total Operating Revenue
N/A
N/A
N/A
N/A
N/A
N/A
Cost of Revenue
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
0
N/A
0
N/A
0
N/A
Sales and Marketing Expense
N/A
N/A
370,500
-79.04%
1.8M
N/A
Research and Development Expense
-2.4M
+8.96%
-2.2M
+41.99%
-1.6M
N/A
Depreciation and Amortization Expense
N/A
N/A
N/A
N/A
N/A
N/A
Total Operating Expenses
10.5M
-13.91%
12.2M
+210.55%
3.9M
N/A
Operating Profit
N/A
N/A
-16.5M
+26.48%
-13.1M
N/A
Interest Income
125,644
+161.76%
48,000
N/A
N/A
N/A
Interest Expense
N/A
N/A
N/A
N/A
-1.6M
N/A
Interest Income and Expense and Net
125,644
+161.76%
48,000
+102.92%
-1.6M
N/A
Total Nonoperating Income and Expense
N/A
N/A
N/A
N/A
1.6M
N/A
Income before Taxes
N/A
N/A
-16.5M
+26.48%
-13.1M
N/A
Income Taxes
N/A
N/A
N/A
N/A
N/A
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
N/A
N/A
-16.5M
+26.48%
-13.1M
N/A
Net Income from Continuing Operations Applicable to Common
N/A
N/A
-16.5M
+26.48%
-13.1M
N/A
Basic EPS and Net Income
-0.33
-158.93%
0.56
+216.67%
-0.48
N/A
Diluted EPS and Net Income
-0.33
-158.93%
0.56
+224.44%
-0.45
N/A
Basic Weighted Average Shares
31.7M
+7.16%
29.5M
+8.18%
27.3M
N/A
Diluted Weighted Average Shares
31.7M
+7.16%
29.5M
+1.80%
29.0M
N/A
Balance Sheet
Cash and Cash Equivalents
7.3M
+475.51%
1.3M
+102,753.86%
1,231
N/A
Short-Term Investments
N/A
N/A
N/A
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
7.3M
+475.51%
1.3M
+102,753.86%
1,231
N/A
Total Current Assets
7.3M
+454.48%
1.3M
+204.21%
435,225
N/A
Accumulated Depreciation
N/A
N/A
N/A
N/A
N/A
N/A
Property and Plant and Equipment and Net
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Assets
200,000
0.00%
200,000
-95.69%
4.6M
N/A
Total Assets
7.3M
+454.48%
1.3M
-72.26%
4.8M
N/A
Income Taxes Payable
N/A
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
N/A
N/A
N/A
N/A
101,000
N/A
Total Current Liabilities
1.4M
+109.70%
680,968
-49.01%
1.3M
N/A
Total Long-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
Total Liabilities
1.4M
+109.70%
680,968
-49.01%
1.3M
N/A
Retained Earnings
-41.0M
+34.03%
-30.6M
+117.55%
-14.1M
N/A
Total Stockholders Equity
N/A
N/A
643,037
-81.30%
3.4M
N/A
Total Shares Outstanding
34.4M
+15.52%
29.8M
+4.03%
28.6M
N/A
Cash Flow
Cash from Operating Activities
-3.7M
-27.26%
-5.1M
+31.37%
-3.9M
N/A
Capital Expenditures
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Investing Activities
N/A
N/A
N/A
N/A
N/A
N/A
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
9.7M
+53.25%
6.3M
+64.14%
3.9M
N/A
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
N/A
N/A
N/A
N/A
Return on Assets
N/A
N/A
-542.25%
N/A
N/A
N/A
Return on Equity
N/A
N/A
-810.18%
N/A
N/A
N/A
Revenue Growth
N/A
N/A
N/A
N/A
N/A
N/A
Current Ratio
5.14
+164.41%
1.94
N/A
N/A
N/A
Cash Ratio
5.10
+174.44%
1.86
N/A
N/A
N/A
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow